Further, we propose a therapeutic strategy that combines EGFR-TKI treatment with inhibitors targeting the TET2/NF-κB axis, offering potential for overcoming this resistance in NSCLC patients. The gene discussed is TET2; the disease is non-small cell lung carcinoma.